Maze Therapeutics Announces FDA Orphan Drug Designation Granted to MZE001 for the Treatment of Pompe…
Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug…
Read More...
Read More...
